Results 161 to 170 of about 106,531 (314)

Regulation of the lncRNA NEAT1 by p53‐ΔNp63 crosstalk modulates the DNA damage response and therapeutic efficacy in HNSCC

Molecular Oncology, EarlyView.
In head and neck squamous cell carcinoma (HNSCC) p53 and p63 exert opposite roles on the transcription regulation of the lncRNA NEAT1. Under basal conditions, p53 levels are low and p63 represses NEAT1 expression. Upon genotoxic stress, p53 is rapidly induced, displacing p63 from the NEAT1 promoter leading to NEAT1 transcriptional activation and ...
Sara De Domenico, Veronica La Banca, Silvia D'Amico, Stefano Scalera, Sara Nicolai, Angelo Peschiaroli   +5 more
wiley   +1 more source

CABIN1 peptide effectively targets MEF2D-fusion protein in B-cell precursor acute lymphoblastic leukemia

Signal Transduction and Targeted Therapy
Subin Cha, Sangho Lee, Han-Teo Lee, Hyonchol Jang, Hong-Duk Youn   +4 more
doaj   +1 more source

SPHINX31 acts as a SRPK1 inhibitor targeting the ATR/DNA‐PKcs/CHK1 replicative checkpoint to inhibit cell growth in non‐small cell lung cancer

Molecular Oncology, EarlyView.
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim, Aurelie Genoux, Nadiia Zubchuk, Haoyang Zheng, Perla Salameh, Theo Ziegelmeyer, Fabien Dalonneau, Margot Rouchette, Christiane Oddou, Simona Miron, Helene Polveche, Adiilah Mamode Cassim, Carmen Garrido, Eleni Nikolakaki, Didier Auboeuf, Tao Jia, Sophie Zinn‐Justin, Beatrice Eymin   +17 more
wiley   +1 more source

Single-Cell Dissection of Inflammatory Suppression and Stemness Plasticity Reveals STMN1-Associated Malignant Epithelial Cells in Severe Lung Cancer. [PDF]

Chem Biol Drug Des
Chen Y, Chen S, Cheng B, Tang Y, Huang Y, Chen M.   +5 more
europepmc   +1 more source

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

Molecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim, Alvin Kunyao Guo, Yoko Itahana, Srinivasaraghavan Kannan, Valerie Goh, Mingmin Ong, Terina Yan Wen Tay, Weiying Ye, Sabhashina Radha Krishnan, Jun Nishiyama, Chandra S Verma, Koji Itahana   +11 more
wiley   +1 more source

Corrigendum: Scorpion Venom Analgesic Peptide, BmK AGAP Inhibits Stemness and Epithelial-Mesenchymal Transition by Down-Regulating PTX3 in Breast Cancer

Frontiers in Oncology, 2021
Sylvanus Kampo, Sylvanus Kampo, Sylvanus Kampo, Bulbul Ahmmed, Tingting Zhou, Tingting Zhou, Lawrence Owusu, Thomas Winsum Anabah, Natacha Raissa Doudou, Eugene Dogkotenge Kuugbee, Yong Cui, Zhili Lu, Qiu Yan, Qing-Ping Wen, Qing-Ping Wen   +14 more
doaj   +1 more source

Integrative single-cell and computational pathology analyses reveal a C11orf24-associated stem-like epithelial population linked to tumor microenvironment remodeling and immune evasion in bladder cancer. [PDF]

Transl Oncol
Wang Y, Zhang S, Luo X, Wang Z, Wang Y, Li N, Liu Y, Gao J, Zhang R, Jia Z, Shi R, Zhang L.   +11 more
europepmc   +1 more source

The “stem” of chemoresistance [PDF]

Cell Cycle, 2010
Giulia, Bertolini, Laura, Gatti, Luca, Roz   +2 more
openaire   +2 more sources

Supplementary Figure 3 from Identification of Colorectal Cancer Cell Stemness from Single-Cell RNA Sequencing

Single-cell stemness signature ...
Kangyu Lin (17619740), George J. Chang (18287445), Elena Bogatenkova (18287448), Oscar E. Villarreal (18287442), David Menter (18287451), Cara L. Haymaker (15033189), Saikat Chowdhury (17078737), John Paul Shen (14937972), Nicholas J. Hornstein (18287439), Mohammad A. Zeineddine (18287433), Fadl A. Zeineddine (18287436), Jean-Nicolas Vauthey (15017243), Dipen M. Maru (15029967), Scott Kopetz (14956778)   +13 more
core   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source